Overview

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer

Status:
Withdrawn
Trial end date:
2019-01-05
Target enrollment:
Participant gender:
Summary
Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
Bevacizumab
Irinotecan